Back to Health

What Is Zidovudine and What Is It For?

What Is Zidovudine and What Is It For?
Bareback Guide 15 July 2026

Zidovudine, also known as AZT, was the first medicine licensed to treat HIV, approved in 1987. It is rarely used in UK first-line treatment today and retains a role in narrow circumstances.

What kind of drug is it?

A nucleoside reverse transcriptase inhibitor, and specifically a thymidine analogue. It was originally developed in the 1960s as a potential cancer treatment, shelved, and then found to be active against HIV two decades later.

How does it work?

HIV must convert its RNA genome into DNA using reverse transcriptase. Zidovudine is converted inside the cell to an active form resembling thymidine, one of the four natural DNA building blocks, which the enzyme incorporates into the growing chain.

What happens then?

The chain terminates, because zidovudine lacks the attachment point the next building block requires. The viral DNA is never completed and the infection cannot establish itself in that cell.

Why does its history matter?

Because it was the first evidence that HIV could be treated at all. Its approval in 1987, after an unusually rapid trial, was a landmark, and it shaped expectations about what treatment could achieve for a generation.

What went wrong with it initially?

It was given alone, at high doses, and resistance emerged within months. The benefit was real and short-lived. That experience is why modern treatment always uses combinations and why monotherapy is never appropriate.

When did that change?

In the mid-1990s, when combination therapy including protease inhibitors transformed outcomes. Zidovudine remained a component of those combinations for years, and better tolerated nucleosides gradually displaced it.

What is it used for now?

Rarely in UK adult first-line treatment. It retains a role in some situations during pregnancy and after birth, in certain resistance patterns, and where other nucleoside analogues cannot be used.

Why is it still used in pregnancy?

Because it has the longest record of any antiretroviral in that setting and remains part of some protocols for reducing transmission during labour and for treating newborns.

Does it cover hepatitis B?

No. Regimens containing it may, through a lamivudine component, and lamivudine alone is not adequate long-term hepatitis B treatment.

Why is it not used more?

Tolerability. Bone marrow suppression, muscle problems, fat loss and mitochondrial toxicity made it considerably harder to live with than modern nucleosides, and better options exist for almost everyone.

Is it available in the UK?

Yes, though rarely prescribed. It is available as tablets, an oral solution and an intravenous formulation, the last used in specific hospital situations.

Is it available generically?

Widely and cheaply, which is one reason it remains in use in some settings internationally where cost matters more than tolerability.

Should you switch if you are on it?

Worth discussing. Anyone still taking zidovudine long term should ask whether a modern alternative would suit them better, since the tolerability difference is substantial.

What is its legacy?

Considerable. It established that antiretroviral therapy was possible, it produced the resistance lessons that shaped combination treatment, and it saved a great many lives during the worst years of the epidemic.

Where does it sit against the alternatives?

Behind every modern nucleoside on tolerability. Its remaining advantages are historical record in pregnancy and activity against certain resistant virus.